The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.
According to the company, it also will increase its roller compaction and fluid bed capacity – and an automated bottling line is currently being installed.
Additionally, a new spray dryer will provide commercial scale-up capacity for projects progressing from early-stage development. This will enable tech transfer of projects from Catalent’s development sites, including San Diego, CA and Nottingham, UK, according to the company.
Equipment validation is expected over the coming months.
Formulation and supply services
In related news, Catalent recently announced that it has successfully provided formulation and supply services for MGB Biopharma’s Phase II clinical trial materials.
Catalent and MGB Biopharma have been working together to formulate and manufacture MGB Biopharma’s leading candidate, MGB-BP-3, an orally-dosed drug for the treatment of Clostridium difficile-associated diarrhea (CDAD).
Also earlier this month, Catalent expanded its hot melt extrusion (HME) capabilities at its drug development center of excellence. Additionally, the company opened its 30,000-square-foot Shanghai, China-based clinical supply facility, which is expected to employ up to 100.